Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)

NCT04314843 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT04314843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04314843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1
Overall status
Terminated
Start date
May 26, 2020
Completion date
July 27, 2022
Enrollment
6 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory large b-cell lymphoma